

ACT-AD

Accelerate Cure/Treatments for Alzheimer's Disease

The Coalition is supported in part by educational grants from:

Elan

Pfizer

Medivation

Eli Lilly

Bristol-Myers Squibb

Eisai

JANSSEN AI

Merck

Novartis

"The best hope for millions of families and for our country is for research and innovation to be translated into real advances in treatment and prevention for Alzheimer's Disease." - Daniel Perry

About the ACT-AD Coalition

ACT-AD is a growing coalition of more than 50 national organizations representing patients, providers, caregivers, consumers, older Americans, researchers and employers seeking to accelerate development of potential cures and treatments for Alzheimer's.

Mission

ACT-AD supports accelerating research for transforming therapies to potentially slow, halt or reverse the progression of Alzheimer's disease.

Goals

ACT-AD seeks:

- Immediate public and government recognition of Alzheimer's disease as a debilitating, dehumanizing and life-threatening disease that requires urgent attention.
- To bring interventional therapies to patients, providers and families in the next decade by making the acceleration of promising Alzheimer's disease therapies a top national priority.

Highlights

2006

- ACT-AD recommends AD reviews be consolidated into one office with intensive neurology expertise (HIV model) ; A series of scientific workshops be conducted for in-line reviewers; and A patient/caregiver program be established
- ACT-AD meets with FDA about lack of urgency on AD and concerns that reviews were split in 3 divisions with varying levels of neurology expertise

2007

- ACT-AD and FDA agree to conduct scientific workshop on clinical meaningfulness in Alzheimer's disease for in-line reviewers
- ACT-AD hosts a follow-up meeting with FDA (CDER/CBER) - FDA forms interagency neurology working group; Agrees to Alzheimer's Allies scientific workshops; and Agrees to patient/caregiver program

2008

- ACT-AD, along with 21 prominent clinicians, sends a letter to top FDA officials demonstrating a growing consensus around the need for inclusion of imaging and biochemical biomarkers in AD trials
- ACT-AD convenes experts' dinner at ICAD 2008 to explore future topics for scientific workshops
- ACT-AD, the Alzheimer's Association, and the Alzheimer's Study Group co-host a scientific workshop on clinical meaningfulness

2009

- ACT-AD commissions a voter sentiment survey to gauge American's attitudes towards Alzheimer's disease, the importance they place on finding a cure for the disease, and what policies they would support to ease the burden of the disease on patients and caregivers; Findings presented on Capitol Hill
- ACT-AD hosts follow-up workshop with FDA, the Alzheimer's Association and LEAD on clinical meaningfulness in early AD
- Working group on Alzheimer's disease biomarkers is launched by the Alliance for Aging Research to further advance consensus on biomarker utility
- ACT-AD advocates for increased appropriations for FDA drug review in FY 2010

2010

- ACT-AD convenes experts' dinner at ICAD 2012 to explore challenges related to the incorporation of biomarkers in AD clinical trials
- ACT-AD, FDA, the Alzheimer's Foundation of America and the Alzheimer's Drug Discovery Foundation hold a scientific workshop on improving Phase II trials for AD
- ACT-AD advocates for increased appropriations for FDA drug review in FY 2011

2011

- ACT-AD represented in monthly meetings with FDA representatives on the reauthorization of the prescription drug and medical device user fee programs
- ACT-AD advocates for increased appropriations for FDA drug review in FY 2012
- ACT-AD convenes an experts' dinner at the CTAD conference on international regulatory issues affecting Alzheimer's therapy development
- Working group on AD biomarkers publishes review in Neurobiology of Aging
- ACT-AD, the Cure Alzheimer's Fund and LEAD hold a scientific workshop with FDA on strategies for designing Phase II trials